Search
 

FDA panel backs expanded use of Merck's Vytorin

Federal health experts are recommending that use of Merck's blockbuster cholesterol drug Vytorin be expanded to patients with kidney disease, but not those with late-stage disease who are on dialysis.

By Associated Press | Updated on November 02, 2011

WASHINGTON (AP) — Federal health experts are recommending that use of Merck’s blockbuster cholesterol drug Vytorin be expanded to patients with kidney disease, but not those with late-stage disease who are on dialysis.

The Food and Drug Administration’s panel of drug experts voted unanimously, 16-0, that data submitted by Merck show the drug is safe and effective for reducing heart attacks, strokes and other problems in kidney disease patients, according to an agency spokeswoman. The panel voted against the same use for patients on dialysis, the standard treatment for patients with failing kidneys who can no longer remove waste from their blood.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Recommended Stories

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2024 ALM Global, LLC. All Rights Reserved.